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Glomerulopathy induced by IgG3 anti-trinitrophenyl monoclonal cryo-
globulins derived from non-autoimmune mice. We have previously
shown that murine IgG3 monoclonal autoantibodies with cryoglobulin
activity, derived from lupus-prone mice, are able to induce glomerular
lesions resembling the "wire-loop" lesion typically described for hu-
man lupus nephritis. In the present study, we have further assessed the
nephritogenic potential of four IgG3 anti-hapten, trinitrophenyl (TNP),
monoclonal antibodies (mAb) obtained from non-autoimmune mice
immunized with TNP-conjugated foreign antigens. Our results showed
that two of four IgG3 anti-TNP monoclonal cryoglobulins were capable
of inducing glomerular lesions, characterized by voluminous intracap-
illary thrombi and mesangial deposition of PAS-positive materials,
which differed from "wire-loop" lesions generated by IgG3 monoclonal
cryoglobulins with autoantibody activities. These anti-TNP monoclonal
cryoglobulins, however, failed to induce glomerular lesions when mice
were kept at 37°C after the mAb administration. This finding formally
proves that the cryoglobulin activity is critically involved in the
development of glomerular lesions induced by IgG3 anti-TNP mAb. In
addition, we have demonstrated a remarkable difference in the nephri-
togenic activities of two IgG3 anti-TNP mAb, which exhibit a marked
sequence homology in the variable regions of their heavy and light
chains (91.5% and 99.1% at the amino acid level, respectively) and an
identical isoelectric point. Our results indicate first, that IgG3 mono-
clonal cryoglobulins are able to generate two different kinds of glomer-
ular lesions, and second, that a subtle difference in variable region
sequences may determine not only the nephritogenic activities, but also
the type of glomerular lesions mediated by IgG3 cryoglobulins.
Murine IgG3 have the unique physicochemical property to
self-associate via non-immunological Fc-Fc interaction, and a
majority of them are able to generate cryoglobulins [1—3]. In
fact, IgG3 are selectively enriched in cryoglobulins isolated
from lupus-prone MRL-lpr/lpr mice, from mice injected with
bacterial lipopolysaccharides or from mice infected with ma-
laria [21. Recently, we and others have shown that IgG3
monoclonal antibodies (mAb) with anti-IgG2a rheumatoid fac-
tor or anti-DNA activity derived from autoimmune MRL-lprllpr
and (NZB x NZW)F1 mice are able to induce, in normal mice,
severe glomerulonephritis [1, 4—7]. Light and electron micro-
scopic studies have shown that glomerular lesions induced by
these IgG3 monoclonal autoantibodies resemble "wire-loop"
lesions, that is, subendothelial accumulation of electron-dense
deposits, characteristically described for human lupus nephritis
[6, 7].
There is substantial evidence that the cryoglobulin activity,
associated with murine IgG3 heavy chain constant region,
appears to play a critical role in the generation of glomerular
lesions [4, 5, 8, 9]; only rheumatoid factor (RF) from MRL-lprI
lpr mice that are able to cryoprecipitate—all from the IgG3
subclass—are nephritogenic, and an IgG 1 class switch variant
of a nephritogenic IgG3 RF mAb fails to induce glomerular
lesions. It is, however, not clear whether any IgG3 monoclonal
cryoglobulins (without autoantibody activities) derived from
non-autoimmune mice can similarly induce "wire-loop"-like
glomerular lesions, and what determines the nephritogenic
activity of IgG3 cryoglobulins. Since not all IgG3 cryoglobulins
were able to induce glomerular lesions [1, 6, 7], differences in
variable regions of heavy and light chains may influence the
potential nephritogenic activity of IgG3 cryoglobulins. To ad-
dress these questions, we have assessed the nephntogenic
potential of IgG3 anti-hapten, trinitrophenyl (TNP), monoclonal
cryoglobulins obtained from non-autoimmune mice immunized
with TNP-coupled foreign antigens [3]. Analysis of two IgG3
anti-TNP cryogenerating mAb, CB 1 and CB6, was particularly
interesting because of a marked sequence homology in the
variable regions of their heavy and light chains [10]. Our results
indicate that two of four IgG3 anti-TNP monoclonal cryoglob-
ulins were able to induce glomerular lesions, but different from
"wire-loop" lesions induced by IgG3 monoclonal cryoglobulins
from autoimmune mice. In addition, we found a remarkable
difference in the nephritogenic activities of CB 1 and CB6 mAb,
despite marked variable region sequence homology.
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Monoclonal IgG3 cryoglobulins-generating antibodies
Three IgG3 anti-TNP mAb (CB1, CB6 and 4H10) and one
IgG3 anti-TNP mAb (Cl 1M) with cryoglobulin activity were
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Fig. 1. Nucleotide and predicted amino acid sequences of VH regions of CBI and CB6 mAb Each nucleotide sequence was compared to the 264
germ-line gene [17] of the VGAM3.8 family. The numbering of amino acid residues and complementarity-determining regions (CDR) are according
to Kabat et a! [27]. Identities are indicated by dashes.
established by fusion of spleen cells from C57BL/6 mice immu-
nized with TNP-keyhole limpet hemocyanin, and from l29/Sv
mice immunized with DNP-lipopolysaccharide, respectively
[3]. A non-cryoprecipitating IgG3 anti-TNP mAb (9A6) was
obtained from BALB/c mice immunized with DNP-lipopolysac-
charide [3]. mAb were purified from ascites by protein A
column chromatography. Isoelectric points (p1) of mAb were
determined by analytical isoelectric focusing (IEF) gel electro-
phoresis as previously described [11].
cDNA cloning and sequencing
Total RNA were prepared from CB 1 and CB6 hybridomas by
the LiC1 method [12]. The first strand of cDNA was synthesized
with an oligo(dT) primer and 10 g of total RNA [13]. For
amplification with Taq DNA polymerase (Cetus Perkin Elmer,
Norwalk, Connecticut, USA) [14], the following primers (5'-3')
were used: VHFORCB (AAGTGCCCAAGCACA) and Cy
(GGATAGACAGATGG) for the heavy chains, and VkFoRcn
(TGTCTGGTGrFGACGGA) and Ck (TGGATGGTGGGAA-
GATG) for the light chains. Polymerase chain reaction (PCR)
was performed following recommendations of the manufacturer
(Cetus Perkin Elmer). The amplified fragments were purified on
2% agarose gel and inserted into pUC18-Sma I vector. The
nucleotide sequences corresponding to the variable region of
the heavy (VH) and the light (Vk) were determined by the
dideoxynucleotide chain termination method using M13 primers
[15], and have been deposited in the EMBL data library
(accession number: X70095-X70098). Predicted amino acid se-
quences were derived from nucleotide consensus sequences of
three independent clones for each Vu and Vk.
In vivo treatment
To study the nephritogenicity of IgG3 anti-TNP mAb,
(BALB/c X C57BL/6)F1 hybrid (BALB x B6) mice pretreated
with pristane were injected intraperitoneally with 1O7 hybri-
doma cells and sacrificed when moribund (generally 9 to 12 days
after the implantation of the hybridomas). In one experiment,
IgG3 CB 1 hybridoma cells were similarly injected into BALB X
B6 mice, and three animals were sacrificed three, six and nine
days after the hybridoma injection. In addition, BALB/c mice
were injected intraperitoneally with 15 mg of IgG3 anti-TNP
mAb purified from ascites and sacrificed 18 hours later. In some
experiments, IgG3 anti-TNP mAb were first kept in a 37°C
water bath for one hour to solubilize any cryoprecipitates
present in preparations, and then 10 mg of mAb were intrave-
nously injected into BALB/c mice. Then, mice were kept at
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Table 1. Serum levels of IgG3 and cryoglobulins, and development
of glomerular lesions in mice injected with CB 1 and CB6 IgG3 anti-
TNP hybridoma cells
IgG3b
Kidney
mAba Day 3 Day 6 Day 9 Cryoglobulinsc lesionsd
CBI 2.3 1.0 7.1 1.8 6.1 2.8 30 9 3.9 0.4
CB6 2.6 2.3 9.6 3,2 16.6 6.4 29 9 0.7 0.6
io hybridoma cells were injected intraperitoneally into 3-month-
old BALB x B6 female mice on day 0b Serum levels of IgG3 (mg/mi) were determined by ELISA on days
3, 6 and 9 (mean of 8 mice 1 SD). Mean concentrations of serum IgG3
before the injection of hybridoma cells were 0.5 0.2 mg/mi
Serum levels of IgG3 cryoglobulins (g/m1) at sacrifice (day 9) were
determined by ELISA (mean of 8 mice 1 SD). Serum IgG3 cryoglo-
bulins were not detectable (<0.1 g/ml) before the injection of hybri-
doma cells
d Semiquantitative values of glomerular lesions on a 0 to 4+ scale
based on the intensity of lesions (mean of 8 mice 1 SD).
room temperature or in a warm room at 37°C, and sacrificed
three hours later.
Isolation of cryoglobulins
Blood samples collected from the retroorbital plexus were
allowed to clot at 37°C for two hours. Aliquots of 100 1 of
serum were placed in glass tubes at 4°C for three days. Then,
samples were centrifuged at 2,500 rpm for 20 minutes. The
precipitates were washed four times with cold PBS (pH 7.3) by
centrifugation and finally solubilized in 4 M urea in the same
volume as the original sample.
Serological assays
Concentrations of IgG3 in sera and cryoglobulins were deter-
mined by IgG3 subclass specific ELISA as described previously
[16]. BUN levels were determined by a kinetic method.
Histopathology
Blocks of major organs were obtained at autopsy, and sec-
tions were stained with hematoxylin and eosin (HE), periodic
acid Schiff (PAS) and phosphotungstic acid reagent. Glomerular
lesions were scored on a 0 to 4 scale, in a blinded fashion, based
on the intensity and extent of histopathological changes. Kid-
neys were studied for the deposition of IgG, C3 and fibrinogen
by direct staining with fluorescein-isothiocyanate-conjugated
rabbit anti-mouse IgG, goat anti-mouse C3 or goat anti-rat
fibrinogen (Cappel Laboratories, Cochranville, Pennsylvania,
USA). Parts of kidneys were fixed in 2% glutaraldehyde,
embedded in Epon and stained with osmium for ultrastructural
examination, performed with a Philips EM 400 T electron
microscope (Rotterdam, The Netherlands).
Results
Determination of the Vii and Vk nucleotide sequences
encoding CBJ and CB6 IgG3 anti-TNP mAb
Direct mRNA sequencing of the VH and Vk regions of CB 1
and CB6 IgG3 anti-TNP mAb has previously shown a marked
structural homology [10]. However, because of technical diffi-
culties, a number of amino acid residues were not certain or
unknown. To determine their complete VH and Vk nucleotide
sequences, we performed cDNA cloning by PCR and DNA
sequencing of CB 1 and CB6 VH and Vk regions. Comparison of
the nucleotide sequence of the VH and Vk regions of CB 1 and
CB6 mAb with a data bank indicates that they are encoded by
variable-VGAM3 .8, diversity-FL 16.1 (for CB 1 mAb) and
FL16.2 (for CB6 mAb), and joining-JH2 genes, and by variable-
Vk19 and joining-Jk2 genes.
Nucleotide and predicted amino acid sequences of CB1 and
CB6 VH and Vk regions are presented in Figures 1 and 2. The
VH regions of CB 1 and CB6 mAb are highly homologous; CB 1
mAb differs from CB6 mAb by 10 amino acid substitutions: one
in complementarity-determining region 1 (CDR1; position 32),
two in framework region 2 (FR2; positions 37 and 40), three in
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Fig. 2. Nucleotide and predicted amino acid sequences of Vk regions of CBJ and CB6 mAb. See also the legend to Fig. I.
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Fig. 3. A and B. Representative histological appearance of glomerular lesions in BALB x B6 mice after the intraperitonea! injection of CBI IgG3
anti-TNP hybridoma cells. Their glomerular lesions are characterized by the voluminous intracapillary deposition of PAS-positive materials which
nearly occlude the capillary lumen (A: PAS, x400). Phosphotungstic acid staining demonstrates substantial amounts of fibrin admixed in
intraluminal deposits of glomeruli (B: x400), C and U. Representative histological appearance of glomeruli in mice after the intraperitoneal
injection of CB6 IgG3 anti-TNP hybridoma cells. Note the absence of significant deposits of PAS-positive materials and fibrin (C: PAS, x400; D:
phosphotungstic acid staining, X400).
FR3 (positions 77, 78 and 94) and four in CDR3 (positions 96 to
99). Among these differences, there are reciprocal substitutions
of charged amino acid residues at position 94 (Ser in CB 1
instead of Arg in CB6) and position 96 (Mg in CB 1 instead of lie
for CB6); however, these changes are unlikely to result in
significant modifications in overall or focal charges of both
mAb. The Vk amino acid sequences of both CB l and CB6 mAb
are essentially identical, differing only at position 80 in FR3 (Pro
in CB1 instead of Ala in CB6).
When compared with VGAM3.8 germ-line genes, the VH
gene encoding CB 1 and CB6 mAb appears to be closely related
to the 264 germ-line gene of BALB/c origin [17]. VH CB 1 differs
from the 264 germ-line gene by six nucleotide substitutions
resulting in five amino acid substitutions, whereas VH CB6
differs from the 264 germ-line gene by one nucleotide substitu-
tion only at codon 37, resulting in the amino acid substitution
(Met for Va!) (Fig. 1). This indicates the presence of more
somatic mutations in the VH segment of the CB I mAb than that
of the CB6 mAb.
Induction of glomerular lesions by CBJ, but not CB6 IgG3
anti-TNP monoclonal cryo globulins
Since both CB 1 and CB6 mAb obtained from C57BL/6 mice
immunized with foreign antigens were previously shown to be
able to generate cryoglobulins [3], we have compared their in
vivo pathogenic potential in BALB x B6 mice by injecting
intraperitoneally hybridoma cells. Serum levels of IgG3 pro-
gressively increased from three days after the implantation of
hybridoma cells (Table 1). Serum IgG3 concentrations in CB 1
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Fig. 4. Immunofluorescence findings of glomerular lesions in BALB X
B6mice after the injection of CBI or CB6 hybridoma cells. Note heavy
deposits of IgU (A), C3 (C) and fibrinogen (E) in glomerular lesions
induced by CB1 mAb, which markedly contrasted with absent or little
deposits (B: IgG; D: C3; F: fibrinogen) in glomeruli from mice injected
with CB6 hybridoma cells (x200).
hybridoma-injected mice were comparable to those injected
with CB6 hybridoma cells until day 6. At the time of sacrifice (9
days after the hybridoma injection), IgG3 levels were more
elevated in mice receiving CB6 hybridoma cells, but similar
amounts of cryoglobulins were recoverable from the sera in
both groups of mice (Table 1).
All animals receiving CB 1 hybridoma cells developed diffuse
glomerular lesions by day 9. By light microscopy, predominant
glomerular changes were characterized by voluminous intra-
capillary PAS-positive thrombi, almost completely obstructing
capillary lumens (Fig. 3A). Immunofluorescence studies
showed markedly positive staining of these glomerular deposits
with anti-mouse IgG and anti-mouse C3 antisera (Fig. 4 A, C).
Mesangial cell proliferation and PMN infiltration were not
evident. The phosphotungstic acid and immunofluorescence
stainings revealed the presence of substantial amounts of fibrin-
fibrinogen admixed in the thrombi (Figs. 3B, 4E). Electron
microscopic examination showed a diffuse and massive plug-
ging of glomerular capillaries by amorphous protein deposits,
and abundant amounts of electron-dense deposits were occa-
sionally located in the cytoplasm of endothelial cells and in the
mesangium (Fig. 5). Notably, no subendothelial deposits resem-
bling "wire-loop" lesions were observed at any moment after
the CB 1 cell injection. In contrast, mice receiving CB6 hybri-
doma cells developed only minimal changes in glomeruli (Fig. 3
C, D) with little glomerular deposits of IgG, C3 and fibrinogen
(Fig. 4 B, D, F). It should be mentioned that mean values (± 1
SD) of blood BUN concentrations in CB I hybridoma-injected
mice at the time of sacrifice were 27.1 4.5 mmollliter,
approximately three times higher than those from CB6 hybri-
doma-injected mice (11.1 0.7 mmollliter; means of pristane-
treated control mice were 7.2 0.6 mmol/liter).
To further confirm differences in nephritogenic activities of
CB1 and CB6 mAb, 15 mg of each mAb were injected intraperi-
toneally into BALB/c mice, and the development of glomerular
lesions was determined 18 hours later. Light microscopical
examination of CB 1 mAb-injected mice showed intracapillary
deposits of PAS- and phosphotungstic acid-positive thrombi in
the majority of glomeruli, whereas CB6 mAb-injected mice
developed deposits only in a limited number of glomeruli (Table
2). Glomerular lesions observed in CB 1 mAb-infused mice were
less severe, but overall glomerular changes were identical to
those induced by the injection of hybridoma cells. Notably, no
significant PMN infiltration and mesangial cell proliferation
were seen. It should be mentioned that essentially identical
results were obtained in mice pretreated with pristane prior to
intraperitoneal infusion of IgG3 anti-TNP mAb (data not
shown). Serum IgG3 levels in CB6 mAb-injected mice were
similar or even higher than those of CB 1 mAb-injected mice,
although cryoglobulin activities were slightly higher in CB 1
mAb-injected mice (Table 2).
When glomerular lesions were sequentially analyzed from
three, six and nine days after the injection of CB 1 hybridoma
cells, the progression of the severity of glomerular lesions was
observed, but the types of lesions were the same. No significant
cellular changes were seen during the observation period, and
at day 6 glomerular intracapillary thrombi became detectable in
only a fraction of glomeruli, ending up with more diffuse lesions
until day 9. It should be mentioned that the glomerular changes
induced by the CB 1 mAb are reminiscent of those seen in
human cryoglobulin-associated nephropathy. However, several
features were lacking: (1) no basement membrane duplication
due to mesangial cell interposition was present, and (2) no
cylindrical or annular structures were seen within the intracap-
illary deposits at high power magnification (x 28,000).
Since it has been proposed that the charge characteristics of
antibodies may play an important role in the glomerular local-
ization of immune complexes [181, we have determined the p1 of
CB 1 and CB6 mAb. In spite of their different nephritogenic
activities, both antibodies exhibit an identical p1(8.8), which is
expected from the remarkable amino acid sequence homology
in the V regions of these two mAb.
Nephritogenic activities of other JgG3 anti-TNP mAb from
non-autoimmune mice
Since the CB 1 IgG3 anti-TNP monoclonal cryoglobulin was
able to induce glomerular lesions, but of a different type from
those induced by IgG3 monoclonal cryoglobulins with autoanti-
body activities derived from lupus-prone mice [6], we further
studied two other IgG3 anti-TNP monoclonal cryoglobulins
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Fig. 5. Electron microscopical findings in
glomerular lesions in BALB x B6 mice after
the injection of CBI hybridoma cells (A:
x5000; B: x8000). A. Prominent electron-
dense deposits within mesangial matrix (M).
Table 2. Serum levels of IgG3 and cryoglobulins, and development
of glomerular lesions in mice injected with CB 1 or CB6 mAb
mAba IgG3" Cryoglobuhinsb Kidney lesionsc
CB1 5.6 1.0 26 8 70 7
CB6 8.0 3.5 16 2 15 10
a 15 mg of CB1 or CB6 mAb was injected intraperitoneally into
3-month-old BALBIc female mice (5 mice in each group)
b Serum levels of IgG3 (mg/mi) and cryoglobulins (g/ml) 18 hr after
the mAb injection (mean of S mice I SD)
% of glomeruli exhibiting cryoglobulin deposits in glomerular cap-
illary lumens (mean of 5 mice 1 SD); 20 glomeruli were examined in
each mice; note that histological lesions induced by a single injection of
15 mg CB1 mAb were less severe than those induced by the CB1
hybridoma injection.
(4H 10 and Cl lM) from non-autoimmune mice for potential
nephritogenic activities. The implantation of hybridoma cells
secreting 4H10 mAb led to the development of glomerular
lesions (Table 3). It should be noted that the type of lesions
were identical to those induced by the CB I mAb: voluminous
intracapillary and mesangial deposits without significant gb-
merular cell proliferation and PMN infiltration. In contrast, no
Table 3. Serum levels of IgG3 and cryoglobulins, and development
of glomerular lesions in mice injected with 4H10, Cl lM and 9A6
IgG3 anti-TNP hybridoma cells
mAb'
Day at
sacrifice IgG3" Cryoglobulins"
Kidney
lesionsc
4H10 10—11 3.3 0.5 32 14 2.8 0.7
C11M 9—11 6.6 2.3 16 2 <0.5
9A6 10—12 18.1 5.8 < 0.1 <0.5
a io hybridoma cells were injected intraperitoneally into 3-month-
old BALB x B6 female mice (5 to 8 mice in each group) on day 0
b Serum levels of IgG3 (mg/mi) and cryoglobulins (gIml) at sacrifice
were determined by ELISA (mean of 5 to 8 mice 1 SD)
Semiquantitative values of glomerular lesions on a 0 to 4+ scale
based on the intensity of lesions (mean of 5 to 8 mice I sr).
Cl lM hybridoma cells. It should be mentioned that serum
levels of IgG3 and cryoglobulins in mice receiving Cl lM
hybridoma cells were comparable or even higher than those
from mice injected with CB 1 or 4H 10 hybridoma cells at day of
sacrifice (Tables 1 and 3). Finally, mice receiving hybridoma
cells secreting the 9A6 IgG3 anti-TNP mAb lacking cryoglobu-
bin activity generated neither cryoglobulinemia nor glomerular
significant glomerular changes occurred in mice injected with lesions.
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Fig. S—continued
B. Higher magnification of a glomerular
capillary loop with adjacent mesangium (M).
Note the presence of numerous electron-dense
deposits in the cytoplasm of endothelial cells
(End) as well as in the mesangium.
Temperature dependency of nephritogenic activities of IgG3
anti-TNP monoc/onal cryoglobulins
To study whether the cryoglobulin activity measured in vitro
is indeed responsible for the glomerular deposition of the two
IgG3 anti-TNP mAb (CB1 and 4HlO), we have analyzed the
development of glomerular lesions in mice kept at 37°C. For this
purpose, prewarmed IgG3 anti-TNP mAb devoid of cryoglob-
ulins were intravenously injected into BALB/c mice, then mice
were kept either at room temperature or in a warm room at 37°C
(3 mice in each group). Three hours later animals were sacri-
ficed, and their glomerular lesions were assessed. All CB1 or
4HlO mAb-injected mice kept at room temperature developed
typical glomerular lesions described above. The majority of
glomeruli showed intracapillary deposits of PAS- and phospho-
tungstic acid-positive thrombi (Fig. 6). In contrast, the devel-
opment of such glomerular lesions were almost completely
prevented when mice were kept at 37°C. Notably, serum levels
of IgG3 were comparable in both groups of mice (data not
shown). Thus, these results indicated that the generation of
cryoglobulins in vivo is critical for the development of glomer-
ular lesions induced by CB1 and 4H10 IgG3 anti-TNP mAb.
Discussion
The present study demonstrates that a fraction of IgG3
anti-TNP monoclonal cryoglobulins derived from non-autoim-
mune mice immunized with TNP-conjugated foreign antigens is
able to generate glomerular lesions, but that the type of lesions
induced by them markedly differs from those induced by IgG3
monoclonal cryoglobulins with autoantibody activities, estab-
lished from MRL-lprllpr and (NZB x NZW)F1 mice. The latter
cryoglobulins induce "wire-loop" lesions typically described
for human lupus nephritis [6, 71. In addition, we have demon-
strated for the first time that murine IgG3 monoclonal cryoglo-
bulins are unable to induce glomerular lesions when mice were
kept at 37°C after the mAb administration. This finding formally
proves that the cryoglobulin activity is critically involved in the
development of glomerular lesions induced by IgG3 anti-TNP
mAb. In addition, we have demonstrated a remarkable differ-
ence in nephritogenic activities of two IgG3 anti-TNP mAb
(CB1 and CB6), which share a marked sequence homology in
their VH and Vk regions and an identical isoelectric point.
It is significant that IgG3 monoclonal cryoglobulins without
autoantibody activity derived from non-autoimmune mice are
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Fig. 6. Representative histological appearance of glomeruli 3 hours after an intravenous injection of 10 mg IgG3 anti-TNP mAb in BALBIc
mice, which were kept either at roon temperature (A) or in a warm room at 37 "C (B). Note the presence of voluminous intracapillary deposits
of PAS-positive materials in glomeruli from mice kept at room temperature (A: PAS, x400), which markedly contrasted with the absence of
significant glomerular deposits in mice kept at 37°C (B: PAS, x400).
able to generate glomerular lesions, but the type of lesions is autoimmune mice [6, 7]. We have recently demonstrated that an
different from "wire-loop" lesions induced by IgG3 monoclonal IgG3 monoclonal cryoglobulin with anti-IgG2a rheumatoid fac-
cryoglobulins with RF or anti-DNA activities obtained from tor activity is capable of producing "wire-loop" lesions in mice,
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independently of the presence of corresponding IgG2a autoan-
tigens [4, 6], and also in mice depleted of C3 (T. Fulpius et a!,
manuscript in preparation). These observations argue against
the idea that the development of two different types of glomer-
ular lesions is related to different capacities of IgG3 cryoglob-
ulins to induce immune complex formation and subsequent
complement activation. Instead, we favor the idea that the
different physicochemical properties of individual cryoglobulins
may be responsible for the generation of different glomerular
lesions. At present, cellular and molecular mechanisms respon-
sible for the generation of the two different types of glomerular
lesions are unknown. However, one of the most significant
differences between these two glomerular lesions was the
presence or absence of the PMN infiltration. In mice receiving
IgG3 RF or anti-DNA cryoglobulins, we observed substantial
infiltration of PMN in the early phase of their glomerular lesions
[1, 4—6], unlike those injected with CB1 hybridoma cells. This
raises a possibility that infiltrating PMN may play a significant
role in the development of "wire-loop" lesions. If so, one can
speculate that the capacity of each IgG3 cryoglobulin to stim-
ulate glomerular cells to produce inflammatory cytokines with
chemotactic activities may be a critical factor to determine the
type of glomerular lesions generated by IgG3 monoclonal
cryoglobulins.
It is striking that CB 1 IgG3 anti-TNP mAb is highly nephri-
togenic as compared with CB6 IgG3 anti-TNP mAb, despite the
fact that their V region sequences are closely related and that
their overall charges, as determined by analytical IEF, are
identical. The absence of significant changes in charged amino
acid residues in their VH and Vk regions further argues against
the idea of the focal charge effect to explain the observed
differences in nephritogenic activities. However, it should be
noted that there exist ten amino acid substitutions in the VH
region, particularly in the diversity segment of the CDR3 (4
different amino acids out of 6). Accordingly, one may speculate
that the difference in amino acid residues in the V regions could
modify physicochemical properties of IgG3 microaggregates,
thereby promoting nephritogenic activities of IgG3 cryoglobu-
lins. In this regard, it is worth mentioning that VH segments of
CB I mAb are apparently more mutated than those of CB6 mAb,
which is consistent with the fact that anti-TNP affinity of the
CB 1 mAb is higher than that of the CB6 mAb [3]. This raises an
attractive hypothesis that the modification of amino acid resi-
dues in the V regions as a result of somatic mutations occurring
during the course of immune responses either against self
antigens, as is the case of RF and anti-DNA autoantibodies in
lupus-prone MRL-Ipr/lpr and (NZB x NZW)F1 mice [19—21], or
against foreign antigens, may lead to the formation of more
pathogenic cryoglobulins. An alternative may be the role of
carbohydrate moiety in the nephritogenicity of IgG3 cryoglob-
ulins, since glycosylation appears to contribute to the cryoglob-
ulin activity of certain cryoglobulins [22]. It has been described
that a variety of oligosaccharide patterns was obtained from
human IgG myeloma proteins [23], and that the glycosylation
pattern of IgG changes during the course of autoimmune
rheumatic diseases, most notably in patients with rheumatoid
arthritis [24] and in lupus-prone MRL-lpr/lpr mice [25, 26].
Thus, one needs to consider the possibility that a structural
difference in oligosaccharide side-chains of IgG3 cryoglobulins
may play a role in the expression of their nephritogenic activi-
ties.
Our previous and present results further emphasize the
importance of physicochemical properties of cryoglobulins in
expression of their pathogenic activities; they determine not
only the nephritogenic potential, but also the type of glomerular
lesions mediated by cryoglobulins. The ability of cryoglobulins
to be precipitated in the glomerular capillary lumen and/or to be
localized in the subendothelial space is likely to be related to
physicochemical properties of each individual cryoglobulin,
which may allow interaction with glomerular structures and/or
stimulation of glomerular cells to produce inflammatory cyto-
kines. Differences in physicochemical properties of cryoglobu-
lins can be determined by V region amino acid sequences and/or
oligosaccharide side-chain sequences. Clearly, the identifica-
tion of molecular and structural basis responsible for the two
different kinds of nephritogenic activities of IgG3 cryoglobulins
is of importance for understanding of the pathogenic mecha-
nisms responsible for the development of glomerular lesions
associated with cryoglobulins.
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Appendix. Abbreviations
mAb monoclonal antibody
RF rheumatoid factor
TNP trinitrophenyl
p1 isoelectric point
IEF isoelectric focusing
PCR polymerase chain reaction
VH variable region of the heavy chain
variable region of the light chain
(BALBIc x CS7BL/6)F1
complementarity-determining region
Vk
BALB x B6
CDR
FR framework region
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